For decades, endometriosis has presented medicine with a puzzle that seems to defy logic. One woman with a few small lesions can be doubled over by pain that disrupts work, sleep, and relationships. Another with a disease that spreads widely across her pelvis may have no symptoms at all.
The staging system doctors use to describe how far endometriosis has spread tells them almost nothing about how much it hurts. New research from Yale School of Medicine may help explain why, pointing to a specific inflammatory molecule that appears to track with endometriosis pain.
The Paradox That Never Made Sense
Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside it, most often on the pelvic peritoneum, the ovaries, and the ligaments behind the uterus. The most widely accepted explanation is retrograde menstruation: menstrual blood flows backwards through the fallopian tubes, and cells within it implant and grow where they should not.
Whatever sets it off, the disease is common and often slow to be named. The World Health Organization estimates that endometriosis affects roughly 10% of reproductive-age women, about 190 million people worldwide, and that the average time to diagnosis runs between four and 12 years.
Symptoms can include painful periods, chronic pelvic pain, heavy or irregular bleeding, pain during sex, bowel and bladder symptoms, fatigue, and infertility. It is one of several conditions that can produce persistent pelvic pain, and its symptoms are so broad and variable that the condition can be slow to recognize.
The strange part has always been the mismatch between what surgeons see and what patients feel. “It has never made complete sense why people could have extensive disease and not have pain,” says Hugh Taylor, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale and the study’s principal investigator.
What the Yale Team Found in the Tissue
To look for a molecular explanation, Taylor’s team compared tissue from patients who had pain with tissue from patients who did not. They analyzed biopsies from nine women with painful endometriosis, three of whom reported severe pain and six mild, alongside 10 women whose endometriosis had been found incidentally during surgery for unrelated conditions and who reported no symptoms.
Using RNA sequencing to read which genes were active in each sample, the researchers identified almost 900 genes expressed differently between the two groups. Many are involved in inflammation. When the team measured protein levels in the same biopsies, the pattern held: the painful lesions carried more inflammatory molecules.
One signal stood out. Levels of a molecule called IL16 rose in step with pain severity.
The findings were published on 10 September 2026 in Molecular Human Reproduction.
Why IL16 Matters More Than Its Name Suggests
Interleukin-16 is a signalling protein with an unusually long research history. First described in 1982 as a lymphocyte chemoattractant factor, it was the original chemical beacon shown to summon immune cells to a site. It draws in CD4-positive T cells, monocytes, and eosinophils, and it can prompt monocytes and macrophages to release further inflammatory messengers, such as IL-1 beta, IL-6, and TNF-alpha.
In other words, IL16 is the kind of molecule that can light a fire and then keep feeding it.
“IL16 might be recruiting immune cells into endometriotic lesions and promote producing more inflammatory cytokines,” says Ramanaiah Mamillapalli, PhD, a research scientist at Yale and the study’s first author. “This cascade might heighten pain and inflammation.”
That cascade could explain something patients have reported for years: a lesion does not have to be large to be loud. If a small patch of tissue generates a disproportionate inflammatory response, it may irritate nearby nerves far more than a larger but quieter implant somewhere else.
Endometriosis Pain Is Not Only a Lesion Problem
The Yale finding fits a broader shift in how researchers understand endometriosis pain. Lesions matter, but they are not the entire story. Inflammatory mediators released by the tissue can sensitize nearby nerve fibers, and over time the nervous system itself can become more responsive to pain, a process known as central sensitization. That helps explain why pain can persist or spread beyond the original site of the disease, even after lesions are removed.
Endometriosis is also more than a pelvic condition. It is increasingly described as a chronic, systemic inflammatory disease, which is why fatigue, bloating, digestive symptoms, and low mood so often travel alongside it.
Why Today’s Treatments Often Miss the Target
Current options include anti-inflammatory painkillers, hormonal contraceptives and progestins that suppress the disease’s activity, GnRH agonists that induce a temporary menopause-like state, and surgery to remove lesions. These help many patients. None, however, was designed around the mechanism that actually generates the pain.
“The things we use typically to treat pain now don’t really get at the root cause of pain,” Taylor says. “Understanding what the source of the pain is and blocking it is likely to be much more effective.”
That distinction matters. A drug that dulls pain and a drug that interrupts the inflammatory loop driving it are not the same thing, even when a patient feels similar relief on a given day.
What This Could Change
If IL16 proves to be a driver rather than a bystander, it becomes a target. The Yale team’s next step is to test whether drugs that block the molecule reduce endometriosis pain, which would place it in a growing group of approaches aimed at the biology of the disease rather than only its symptoms.
For now, that work lies ahead. IL16 is a promising lead, not a treatment.
What the Study Does Not Prove
Several limits are worth holding in view. The study analyzed 19 biopsies, enough to show a strong association but not to establish cause and effect. The differences found show that painful endometriosis looks biologically distinct from asymptomatic endometriosis, not that IL16 alone produces the pain.
Pain is also subjective, and capturing it through a small sample has real constraints. IL16 is almost certainly one player among many: inflammation, hormones, nerve growth, and immune activity all interact in ways that are still being mapped.
What the finding does offer is a specific, testable hypothesis where the field previously had generalities.
If Your Pain Has Been Dismissed
One of the most practical implications of the study is also the simplest. Pain and disease extent are not the same measure, and a small amount of endometriosis can be genuinely disabling.
“People need to know that even a little bit of disease can actually cause a lot of pain and to not let anybody dismiss those concerns,” Taylor says.
For anyone living with persistent pelvic pain, that means treating severe symptoms as a reason to keep pursuing assessment and specialist care, not as evidence that something is being exaggerated.
Key Takeaways
- Yale researchers found almost 900 genes expressed differently in painful versus painless endometriosis tissue.
- Elevated levels of the inflammatory molecule IL16 tracked with greater pain severity.
- The finding may help explain why small lesions sometimes cause severe endometriosis pain while extensive disease can be silent.
- A drug that blocks IL16 is a future possibility, not a current option.
- Disease stage is not a measure of suffering, and pain deserves to be taken seriously on its own terms.
